Pfizer
Joel Schrock, Ph.D. has extensive experience in strategy and portfolio management within the pharmaceutical industry, working for Pfizer as a Senior Director and Team Leader. Prior to Pfizer, Joel was a Fund Manager at Big Red Ventures and a Graduate Student Researcher at Memorial Sloan-Kettering Cancer Center. Joel is also a Founding Member and Board Advisor of the Bench to Bedside Initiative, showcasing their dedication to entrepreneurial education. With a Ph.D. in Pharmacology and an MBA, Joel's diverse background and expertise make him a valuable asset in the healthcare and business sectors.
This person is not in any teams
Pfizer
606 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.